MedTrace Logo

Haploidentical NK Cells After Pemetrexed in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)

NCT03366064 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2019-07-08

No results posted yet for this study

Summary

This phase 1 trial investigate safety and maximum tolerated dose of natural killer (NK) cells derived from haploidentical family donors in patients with non-small cell lung cancer

Conditions

Interventions

BIOLOGICAL

Pemetrexed and donor-derived NK cell infusion

Patients are administered with donor-derived NK cells one week after pemetrexed infusion

Sponsors & Collaborators

  • Korea Research Institute of Bioscience & Biotechnology

    collaborator OTHER_GOV

  • Asan Medical Center

    lead OTHER

Principal Investigators

  • Kyoo-Hyung Lee, MD · University of Ulsan, Asan Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-09
Primary Completion
2018-09-03
Completion
2019-06-15

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03366064 on ClinicalTrials.gov